Personalized targeted therapy of moderate and severe atopic asthma in Russia

Personalized targeted therapy of moderate and severe atopic asthma in Russia

Introduction. Taking into account the prevalence of asthma and especially severe atopic asthma which requires carefully selected and expensive therapy, the appearance of the domestic biosimilar omalizumab among biological therapy drugs makes the choice of treatment for this category more affordable....

Full description

Bibliographic Details
Main Authors: D. S. Kulichenko, K. S. Pavlova, O. M. Kurbacheva, N. I. Ilina
Format: Article
Language:Russian
Published: Remedium Group LLC 2022-04-01
Series:Медицинский совет
Subjects:
atopic asthma
monoclonal antibodies
immunobiological therapy
omalizumab
biosimilar
Online Access:https://www.med-sovet.pro/jour/article/view/6765

Similar Items

Similar Items